Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.67 |
| ▸ | PDE1A | P54750 | 1/20 | 0.64 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.64 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.64 |
| ▸ | PDE6C | P51160 | 2/20 | 0.62 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.62 |
| ▸ | PDE6D | O43924 | 1/20 | 0.59 |
| ▸ | PDE6A | P16499 | 1/20 | 0.59 |
| ▸ | PDE6G | P18545 | 1/20 | 0.59 |
| ▸ | PDE6B | P35913 | 1/20 | 0.59 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197233 | 0.94 | PDE5A (0.72) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL6197841 | 0.81 | PDE5A (0.71) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL6199648 | 0.81 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL2566273 | 0.80 | PDE5A (1.00) | PDE5APDE6CPDE11A | |
| SCHEMBL6197392 | 0.79 | PDE5A (0.83) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL6198473 | 0.78 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL6193514 | 0.78 | PDE5A (0.57) | PDE5APDE6C | |
| SCHEMBL2568411 | 0.78 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL5239052 | 0.78 | PDE5A (0.45) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL6198973 | 0.77 | PDE5A (0.62) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995751-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6407114-B1 | BENIGN PROSTATIC HYPERPLASIA, CARDIOVASCULAR, GASTROINTESTINAL AND RESPIRATORY DISORDER TREATMENT; ANTIASTHMATIC, ANTIALLERGEN, AND ANTIDIABETIC AGENTS | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |